Internet Explorer 6 is not supported
This site has been built to work in either Internet Explorer 8 and above, Firefox, Chrome or Safari. For a better experience of using this site, please switch your browser or install Chrome Frame
Citywire Global
menu search
Register to get unlimited access to all of Citywire’s Fund Manager database. Registration is free and only takes a minute.

MIV Global Medtech Fund P1

Ranked 99 out of 125 in - Pharmaceuticals & Health Care over 12 months
All calculations are in USD
Showing fund performance globally. You can view performance in individual jurisdictions.

Performance

Pharmaceuticals & Health Care over : 30/06/2013 - 30/06/2014
  • Rank 99/125 Total Return
  • Rank 12/125 Standard Deviation
  • Rank 42/125 Max Drawdown
Fund Name Risk
10 ESAF Pharmafund, FI

2.8

11 Eurizon Azioni Salute e Ambiente

2.8

12 Candriam Equities B Global Health Care C Cap

2.8

12 MIV Global Medtech Fund P1

2.8

14 FIM Biomed

Currency exposure is hedged

Currency exposure is hedged

2.8

Total Return

Quarterly Performance

to 30/06/2014 Annual Q1 Q2 Q3 Q4
2014 10.3% 5.9% 4.2%
2013 30.4% 12.7% 1.8% 4.4% 8.8%
2012 25.8% 15.2% 2.2% 9.9% -2.8%
2011 -10.1% 1.7% 5.9% -17.0% 0.6%
2010 19.3% 6.3% -6.9% 8.3% 11.3%
2009 38.9% -7.8% 20.7% 16.6% 6.9%
2008 -30.4% -4.2% -4.4% -24.1%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. Austria
  2. Germany
  3. Liechtenstein
  4. Luxembourg
  5. Switzerland

Fund Info

  • Launch date11/03/2008
  • Share Class size115Mn
  • Base currencyCHF
  • ISIN LU0329630999

Purchase Info

  • Min. initial investment1
  • Min. additional investment0

Charges

  • Annual management1.4%

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in USD).

We use cookies to give you the best experience on our website. You can continue to use the website and we'll assume that you are happy to receive cookies. If you would like to, you can find out more about cookies and managing them at any time here. This site is for Professional Investors only, please read our Risk Disclosure Notice for Citywire’s general investment warnings